Global Poloxamer 188 Excipients Market Growth 2024-2030
Poloxamer 188 is a pharmaceutical excipient. It is a nonionic linear copolymer having an average molecular weight of 8400 Daltons and is also referred to as PLURONIC F68, FLOCOR and RheothRx. The copolymer was approved by the FDA nearly 50 years ago as a therapeutic reagent to reduce viscosity in the blood before transfusions.
The global Poloxamer 188 Excipients market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Poloxamer 188 Excipients Industry Forecast” looks at past sales and reviews total world Poloxamer 188 Excipients sales in 2023, providing a comprehensive analysis by region and market sector of projected Poloxamer 188 Excipients sales for 2024 through 2030. With Poloxamer 188 Excipients sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Poloxamer 188 Excipients industry.
This Insight Report provides a comprehensive analysis of the global Poloxamer 188 Excipients landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Poloxamer 188 Excipients portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Poloxamer 188 Excipients market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Poloxamer 188 Excipients and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Poloxamer 188 Excipients.
United States market for Poloxamer 188 Excipients is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Poloxamer 188 Excipients is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Poloxamer 188 Excipients is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Poloxamer 188 Excipients players cover BASF, Croda, Hubei Hengshuo Chemical, Nanjing Well Pharmaceutical, CD Formulation, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Poloxamer 188 Excipients market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Micronized Poloxamer 188
Ordinary Poloxamer 188
Segmentation by Application:
Injectable Formulation
Oral Formulation
Topical Formulation
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
BASF
Croda
Hubei Hengshuo Chemical
Nanjing Well Pharmaceutical
CD Formulation
Key Questions Addressed in this Report
What is the 10-year outlook for the global Poloxamer 188 Excipients market?
What factors are driving Poloxamer 188 Excipients market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Poloxamer 188 Excipients market opportunities vary by end market size?
How does Poloxamer 188 Excipients break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.